首页> 外文期刊>Current diabetes reviews >Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
【24h】

Diabetes and Its Complications: Therapies Available, Anticipated and Aspired

机译:糖尿病及其并发症:可用、预期和期望的疗法

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Worldwide, diabetes ranks among the ten leading causes of mortality. Prevalence of diabetes is growing rapidly in low and middle income countries. It is a progressive disease leading to serious co-morbidities, which results in increased cost of treatment and over-all health system of the country. Pathophysiological alterations in type 2 diabetes (T2D) progressed from a simple disturbance in the functioning of the pancreas to triumvirate to ominous octet to egregious eleven to dirty dozen model. Due to complex interplay of multiple hormones in T2D, there may be multifaceted approach in its management. The 'long-term secondary complications' in uncontrolled diabetes may affect almost every organ of the body, and finally may lead to multi-organ dysfunction. Available therapies are inconsistent in maintaining long term glycemic control and their long term use may be associated with adverse effects. There is need for newer drugs, not only for glycemic control but also for prevention or mitigation of secondary microvascular and macrovascular complications. Increased knowledge of the pathophysiology of diabetes has contributed to the development of novel treatments. Several new agents like Glucagon Like Peptide - 1 (GLP-1) agonists, Dipeptidyl Peptidase IV (DPP-4) inhibitors, amylin analogues, Sodium-Glucose transport -2 (SGLT-2) inhibitors and dual Peroxisome proliferator-activated receptor (PPAR) agonists are available or will be available soon, thus extending the range of therapy for T2D, thereby preventing its long term complications. The article discusses the pathophysiology of diabetes along with its co-morbidities, with a focus on existing and novel upcoming antidiabetic drugs which are under investigation. It also dives deep to deliberate upon the novel therapies that are in various stages of development. Adding new options with new mechanisms of action to the treatment armamentarium of diabetes may eventually help improve outcomes and reduce its economic burden.
机译:在世界范围内,糖尿病是十大死亡原因之一。糖尿病患病率在低收入和中等收入国家迅速增长。它是一种进行性疾病,导致严重的合并症,导致治疗成本增加,并导致该国整体卫生系统增加。2 型糖尿病 (T2D) 的病理生理学改变从胰腺功能的简单紊乱发展到三巨头到不祥的八位字节,再到令人震惊的十一到肮脏的十二个模型。由于 T2D 中多种激素的复杂相互作用,其管理可能采用多方面的方法。不受控制的糖尿病的“长期继发性并发症”可能影响身体的几乎每个器官,最终可能导致多器官功能障碍。现有的疗法在维持长期血糖控制方面并不一致,长期使用可能与不良反应有关。需要更新的药物,不仅用于控制血糖,还用于预防或减轻继发性微血管和大血管并发症。对糖尿病病理生理学知识的增加有助于开发新的治疗方法。几种新药,如胰高血糖素样肽-1(GLP-1)激动剂、二肽基肽酶IV(DPP-4)抑制剂、胰岛淀粉样蛋白类似物、钠-葡萄糖转运-2(SGLT-2)抑制剂和双过氧化物酶体增殖物激活受体(PPAR)激动剂已经上市或即将上市,从而扩大了T2D的治疗范围,从而防止了其长期并发症。本文讨论了糖尿病的病理生理学及其合并症,重点关注正在研究的现有和新型即将到来的抗糖尿病药物。它还深入研究了处于不同发展阶段的新疗法。在糖尿病的治疗武器中增加具有新作用机制的新选择可能最终有助于改善结果并减轻其经济负担。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号